Key facts
- Monopar Therapeutics presented phase 2 data on obatoclax for Wilson disease.
- Obatoclax is a novel small molecule.
- Trial results showed a significant reduction in copper levels in patients.
Wilson disease is a rare genetic disorder that causes copper to accumulate in the body. Obatoclax is a novel small molecule being developed by Monopar Therapeutics. This data presentation is a key step in the drug's development pipeline.